1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
1 citations
,
July 2020 in “The Egyptian Journal of Hospital Medicine” The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.
The treatment was not recommended due to limited effectiveness and significant side effects.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
11 citations
,
May 2010 in “Journal of the South African Veterinary Association” Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.
16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
4 citations
,
December 2020 Methotrexate may help stabilize frontal fibrosing alopecia.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
January 2026 in “Dermatologic Therapy” Folliculotropic Mycosis Fungoides requires stage-based treatment, with early stages using skin therapies and advanced stages needing aggressive treatments.
January 2023 in “National journal of physiology, pharmacy and pharmacology” Low-dose methotrexate is generally safe but can cause mild to severe side effects, and folic acid can reduce these risks.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
9 citations
,
January 2004 in “Journal of dermatological treatment” Rifampicin effectively treated tufted hair folliculitis with no relapse after one year.
32 citations
,
July 2017 in “Oncotarget” Alternating treatment with two drugs could help cells in a rapid aging disease.
8 citations
,
January 2005 in “SKINmed Dermatology for the Clinician” FMF and mycosis fungoides are variants of the same disease, and bexarotene can be an effective treatment.
3 citations
,
December 2015 in “Musculoskeletal care” Many patients on methotrexate experience significant side effects but still continue the medication.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
23 citations
,
March 2019 in “AIDS Care” Remembering to take PrEP is the main challenge, and urine monitoring is a preferred adherence method.
January 2009 in “Journal of Pakistan Association of Dermatology” Systemic cyproterone acetate and 5% topical minoxidil are effective and safe for treating female pattern hair loss.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
80 citations
,
August 1991 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
April 2024 in “Journal of endocrinological investigation” Topical minoxidil helps transgender individuals assigned female at birth grow more facial hair.
August 2021 in “Acta Haematologica Polonica” Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.
27 citations
,
February 2017 in “Clinical, Cosmetic and Investigational Dermatology” New compounds were found to help increase hair growth and decrease hair loss.
September 2024 in “Journal of Skin and Stem Cell” MMP® with minoxidil may improve hair growth in chronic telogen effluvium.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.